SELLAS Life Sciences Group, Inc. SLS

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Galinpepimut-S: Highly Novel and Engineered Immunotherapy Targeting the WT1 Antigen

Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications.

Last close 11.54 2026-10-23
Market cap $2.33B 2026-06-30 share count
52-week range 1.39 - 15.88

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.25

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue ——$0$1.0M$7.6M$1.9M$0———
Cost of revenue $0$0$0$100.0K$200.0K$0————
Gross profit ——$0$900.0K$7.4M$1.9M————
R&D ————$15.7M$9.3M$7.3M$8.8M$6.1M$11.4M
SG&A $12.3M$12.4M$13.9M$12.6M$11.3M$9.6M$9.9M$12.8M$15.1M$4.6M
Total operating expenses $28.3M$31.5M$37.9M$43.0M$32.9M$18.9M$20.0M$31.1M$23.0M$31.9M
Operating income -$28.3M-$31.5M-$37.9M-$42.0M-$25.3M-$17.0M-$20.0M—-$23.0M-$16.0M
Interest expense ——$525.0K$317.0K$6.0K$26.0K$118.0K$266.0K$462.0K$1.2M
Pre-tax income -$26.9M-$30.9M-$37.3M-$41.3M-$20.9M-$16.8M-$19.4M-$29.0M-$23.5M-$17.7M
Income tax $0$0$0$0$237.0K$17.0K$81.0K$1.4M$253.0K$1.0K
Net income -$26.9M-$30.9M-$37.3M-$41.3M-$20.7M-$16.8M-$19.3M-$27.7M-$23.8M-$17.7M
EPS, basic -0.25-0.50-1.34-2.13-1.34-2.11————
EPS, diluted -0.25-0.50-1.34-2.13-1.34-2.11-10.92-157.72-10.44-18.66
Shares, diluted (wtd. avg.) 109.1M61.2M27.8M19.4M15.5M8.0M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $71.8M$13.9M$2.6M$17.2M$21.5M$35.4M$7.4M$5.5M$12.8M$6.0M
Total current assets $75.2M$16.3M$3.2M$17.8M$23.0M$36.9M$8.2M$5.8M$13.1M$6.4M
Property, plant and equipment —————————$199.0K
Goodwill $1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$5.9M
Total assets $78.3M$19.4M$6.2M$20.9M$26.3M$46.0M$16.6M$16.9M$33.5M$6.4M
Accounts payable $2.9M$3.5M$5.6M$3.4M$2.1M$4.7M$3.9M$3.8M$11.7M$840.0K
Short-term debt ———————$0$8.4M$16.4M
Total current liabilities $7.0M$9.5M$13.7M$15.5M$5.0M$12.3M$5.3M$6.0M$24.6M$5.8M
Long-term debt ———————$0$2.6M—
Total liabilities $7.5M$10.0M$14.2M$16.1M$5.9M$18.1M$10.5M$11.7M$31.5M$11.4M
Retained earnings -$275.0M-$248.1M-$217.2M-$179.9M-$138.6M-$117.9M-$101.1M-$81.9M-$54.2M-$30.4M
Total equity $70.9M$9.5M-$8.0M$4.9M$20.3M$28.0M$6.1M$5.2M$2.1M-$5.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$28.4M-$35.4M-$31.4M-$23.8M-$26.0M-$10.4M-$17.6M-$30.4M-$11.0M-$11.8M
Depreciation and amortisation —————————$3.0K
Stock-based compensation $2.0M$1.6M$2.1M$1.7M$1.0M$578.0K$573.0K$395.0K$3.2M$354.0K
Capital expenditure —————————$6.0K
Investing cash flow —$0-$5.5M-$4.5M$0——$0$12.2M-$85.0K
Financing cash flow $86.3M$46.8M$22.3M$24.1M$12.1M$38.4M$19.6M$23.1M$5.5M$16.5M
Dividends paid ——————$0$487.0K$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-047693.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -60M -40M -20M 0 20M Net income, FY2016: -17.7M Net income, FY2017: -23.8M Net income, FY2018: -27.7M Revenue, FY2019: 0 Net income, FY2019: -19.3M Revenue, FY2020: 1.9M Gross profit, FY2020: 1.9M Net income, FY2020: -16.8M Revenue, FY2021: 7.6M Gross profit, FY2021: 7.4M Net income, FY2021: -20.7M Revenue, FY2022: 1M Gross profit, FY2022: 900K Net income, FY2022: -41.3M Revenue, FY2023: 0 Gross profit, FY2023: 0 Net income, FY2023: -37.3M Net income, FY2024: -30.9M Net income, FY2025: -26.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — $0 $1.9M $7.6M $1.0M $0 — —
Gross profit — — — — $1.9M $7.4M $900.0K $0 — —
Net income -$17.7M -$23.8M -$27.7M -$19.3M -$16.8M -$20.7M -$41.3M -$37.3M -$30.9M -$26.9M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Other event Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%